Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
|Articles|August 9, 2010
- Psychiatric Times Vol 27 No 7
- Volume 27
- Issue 7
July 2010 Issue Quiz
What's the annual nonfatal violent crime rate against Psychiatrists? How often is ADHD in adults correctly diagnosed? These questions and more from the July 2010 issue of Psychiatric Times.
Advertisement
Articles in this issue
about 16 years ago
Managing a Psychiatric Emergencyabout 16 years ago
Safety in the Evaluation of Potentially Violent Patientsabout 16 years ago
Psychiatric Emergencies in the Elderlyabout 16 years ago
Enhancing Clinician Safety and Managing Psychiatric Emergenciesabout 16 years ago
Mental Health Parity Law Under Attackabout 16 years ago
On the Instability of Diagnoses Across Timeabout 16 years ago
Integrative Management of ADHD: What the Evidence Suggestsabout 16 years ago
The Rise and Fall of the Biopsychosocial Modelabout 16 years ago
Concentrationabout 16 years ago
Taking the Helm With Gratitude-To Boldly GoAdvertisement
Related to this article
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Advertisement
Advertisement
Trending on Psychiatric Times
1
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
2
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
3
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
4
From Side Effect to Target: Rethinking Metabolic Dysfunction in Psychiatry
5